Another Chinese Innovative Drug Receives FDA Fast Track Designation for Hereditary Angioedema

　　【Pharmaceutical Network Industry Dynamics】Fast Track Designation is a special designation introduced by the U.S. Food and Drug Administration (FDA), aiming to accelerate the approval of drugs for the treatment of serious diseases or to meet unmet medical needs, benefiting patients. On March 16, 2026, Argo Biopharma announced that its investigational siRNA therapy, BW-20805, received Fast Track Designation from the FDA for the treatment of Hereditary Angioedema (HAE).
 

HAE is a rare hereditary disorder, the main characteristic of which is sudden unpredictable swelling in multiple parts of the body. For patients with severe conditions, laryngeal edema may occur as an emergency, and the mortality rate of such complications is approximately 40%, posing a serious threat to the patient's life. According to relevant data estimates, about 1.5 people per 100,000 globally are affected by this disease, highlighting its rarity.
 

Data shows that Argo's BW-20805 is an siRNA therapy targeting prekallikrein (PKK), which inhibits the expression of PKK by targeting PKK mRNA, offering the potential for long-term prevention of HAE attacks. PKK is a well-validated therapeutic target in the field of HAE treatment. Argo is currently conducting a Phase II clinical trial in adult HAE patients, with the Phase II trial expected to be completed in the second half of 2026, followed by the initiation of a Phase III clinical study. Relevant representatives from Argo stated that the granting of Fast Track designation reflects the significant unmet medical needs of the HAE patient population and affirms the potential of BW-20805 as a novel treatment option.
 

It is reported that the Fast Track designation established by the FDA is a special program specifically designed to accelerate the drug development process and expedite the review timeline. This designation is primarily applicable to investigational drugs intended for the treatment of serious diseases and which have the potential to address unmet medical needs. Once a drug receives this designation, the sponsor can engage in early and frequent communication with the FDA throughout the drug development and review process, not only resolving R&D issues promptly but also having the opportunity to qualify for rolling review of the new drug application. Additionally, when the sponsor submits a new drug application and meets relevant criteria, products with Fast Track designation may also be eligible for priority review, further shortening the time to market.
 

According to the review, since 2026, multiple innovative drugs produced in China have received this qualification. For instance, on January 14, Leads Biolabs' PD-L1/4-1BB bispecific antibody LBL-024 also obtained the Fast Track designation from the U.S. FDA.
 

Data shows that LBL-024 is a bispecific antibody targeting both PD-L1 and 4-1BB, representing a therapy targeting the 4-1BB receptor that has reached the registrational clinical stage for extrapulmonary neuroendocrine carcinoma. In Phase II or registrational clinical trials for three indications—non-small cell lung cancer, small cell lung cancer, and extrapulmonary neuroendocrine carcinoma—the product has demonstrated potential. LBL-024 also has the potential to become an approved drug for the treatment of advanced extrapulmonary neuroendocrine carcinoma. Leveraging the company's self-developed and intellectual property-protected X-body platform, the product adopts an optimized 2:2 structural design, which can relieve PD-1/L1 immune suppression and enhance 4-1BB-mediated T-cell activation, achieving synergistic tumor elimination. It exhibits broader cancer treatment potential than PD-1/L1 inhibitors.
 

On January 29, Shanghai Huanma Biotech also announced that its self-developed circular RNA drug, HM2002 Injection, has been granted Fast Track designation by the FDA, accelerating the global R&D and clinical translation process of the drug.
 

As a circular RNA drug, HM2002 is developed based on the core technology platform independently researched and developed by Huanma Biotech. With its covalent closed-loop structure, it possesses the core advantages of high stability and low immunogenicity, and can promote therapeutic angiogenesis in ischemic myocardial regions through specific molecular mechanisms, fundamentally improving myocardial microcirculation function. Not long ago, via epicardial injection, this drug successfully established a dual delivery platform parallel to endocardial injection, providing comprehensive coverage from...Surgical OperationIntervention in the diversified clinical scenarios of transcatheter interventional therapy provides personalized and differentiated treatment options for patients at different stages and with varying conditions, demonstrating broad clinical application prospects.
 

Behind the FDA Fast Track designation for China-produced innovative drugs lies the continuous efforts and breakthroughs of Chinese pharmaceutical companies in core technology areas, as well as a significant outcome of the global strategic layout of these innovative drugs. These drugs target diseases with urgent clinical needs and limited treatment options, and the acceleration of their development process is expected to provide new treatment choices for patients.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.